Pharmacy Times March 14, 2025
Aislinn Antrim, Managing Editor, Matthew Zirwas, MD

Matthew Zirwas, MD, addresses the significant financial burden associated with the medication, emphasizing the importance of pharmacists in navigating prior authorizations and access patient support programs.

In an interview with Pharmacy Times, Matthew Zirwas, MD, discusses the challenges and benefits of using ruxolitinib (Opzelura; Incyte) for atopic dermatitis and vitiligo. He addresses the significant financial burden associated with the medication, emphasizing the importance of pharmacists in navigating prior authorizations and accessing patient support programs. Zirwas also highlights the ease of patient compliance with ruxolitinib due to its rapid symptom relief, particularly for atopic dermatitis. For vitiligo, he stresses the need for patient education and ongoing communication, recommending the use of selfies to track and visualize subtle improvements, which can encourage...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Interview / Q&A, Pharma, Pharma / Biotech, Trends
MHE Week in Review – New PBM Reform Bill, Cardiac Diseases Cost
Walgreens PE Buyout Heavily Reliant on 83% Debt, Raising Concerns About Financial Stability
Pharma Pulse 3/14/25: Navigating Internal Constraints and Uncertainty, Health Plan Support During Natural Disasters & more
Azurity Pharmaceuticals Completes Covis Pharma Acquisition
Over 300 Pharmacy Closures Reported in the Last 3 Months

Share This Article